American Academy of Dermatology

Expert Christine Ko, M.D., FAAD, discusses case reports exploring the variability of skin manifestation in patients with or suspected of COVID-19 infection.

Most skin manifestations associated with COVID-19 resolve as the disease progresses, says expert Christine Ko, M.D., FAAD. But there is one type of lesion that providers and patients will not want to ignore, she warns.

Learn about the histopathology of skin findings associated with potential COVID-19 infection from expert Christine Ko, M.D., FAAD.

Botulinum toxin may help address erythema and flushing in patients with refractory rosacea, according to data presented by Hema Sundaram, MA, MD, FAAD, at the AAD Virtual Meeting Experience (VMX) on June 12.

In this video, Hema Sundaram, MA, MD, FAAD, shares pearls on fat grafting from her presentation at the AAD Virtual Meeting Experience (VMX) in June.

Hema Sundaram, MA, MD, FAAD, breaks down how botulinum toxin can be used to treat scars, a topic she discussed during her presentation at the AAD Virtual Meeting Experience (VMX) on June 12.

Phase 3 data announced at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020 demonstrate that the second-generation IL-17 inhibitor may offer long-lasting, safe treatment for patients with psoriasis.

In our first episode of The Cutaneous Connection, Adam Friedman, M.D., FAAD, discusses his recent presentation at the first virtual American Academy of Dermatology meeting about cannabinoids use in dermatology.

Experts sent a letter to the White House Coronavirus Task Force March 24, outlining concerns about a growing shortage of medications required for managing patients with lupus and rheumatoid arthritis after President Donald Trump said in a March 19 press conference that the anti-malaria drug hydroxychloroquine could treat COVID-19.

As the national pandemic continues to escalate, the American Academy of Dermatology is actively compiling resources related to the novel coronavirus to support its members and their practices. 

The American Academy of Dermatology (AAD) has issued interim recommendations for practitioners to balance the risk of immunosuppression with the risk of disease flare amid COVID-19 pandemic.

The good news for the specialty is practice model options are aplenty and there’s something for every dermatologist. Betsy Wernli, M.D., discussed factors behind dermatologists opting out of solo practice and misperceptions around various practice models Saturday at the Summer meeting of the American Academy of Dermatology.

Betsy Wernli, M.D., president, Forefront Dermatology, offers insights into pros and cons of various practice model options.

The narrative about food, diet and atopic dermatitis recently changed significantly after publication of the Learning Early About Peanut study, says Peter Lio, M.D. Diet matters, and he discusses in what ways.

Patients on powerful immunocompromising agents might be predisposed to infections; however the potential association between biologic agents and increased risk isn’t necessarily universal, Whitney High, M.D., reported during the summer meeting of the American Academy of Dermatology.

There have been several shifts over time around beliefs in the association between diet and acne. Linda Stein Gold, M.D., discussed the recommendations of current guidelines at the summer meeting of the American Academy of Dermatology.

GEP testing could improve staging accuracy and help streamline disease management, but more research is needed to determine if a high-risk GEP classification is associated with improved response to newer systemic therapies.

Kimberly S. Salkey, M.D., shares answers to some of the most common questions she encounters from patients about OTC hair loss treatments.

Check back for highlights from key speakers at this year's Summer AAD meeting in New York City. 

In psoriasis, many therapies offer roughly the same level of care, but that doesn’t mean any patient will respond well to any therapy. According to Mark Lebwohl, M.D., physicians should consider each treatment option in light of a patient's specific comorbidities. 

Why do biologics lose efficacy over time? This physician discusses factors dermatologists should consider when they see this issue in their patients.

Hosted by Dermatology Times and supported by Ortho Dermatologics, the hall of fame honored its inaugural class of inductees at the Long View Gallery in Washington, D.C., just before the 2019 American Academy of Dermatology Annual Meeting.

Continued research has led to a variety of melanoma immunotherapy medications, leading to improved survival of melanoma patients. Clinicians should have a firm grasp of the immune mechanisms behind these novel therapies to provide the best advice on treatment and management options of their melanoma patients

Superficial radiation therapy is experiencing a renaissance in dermatologic therapy due to the modernized equipment and updated guidelines, as well as excellent treatment outcomes for patients with NMSC which rival those seen with other approaches, including Mohs surgery.

Key developments among new and emerging treatments for acne and rosacea include a novel oral agent and a novel topical agent, as well as new formulations of existing products, says Diane S. Berson, M.D. in her presentation at AAD.

Curbing use of antibiotics to treat acne has been challenging despite updated guidelines supporting limited use and the growing problem of bacterial resistance. But things seem to be changing for the better, says Diane M. Thiboutot, M.D.

Scars caused by acne can be both physical and emotional. Helping patients get the care they need starts with recognizing and addressing psychosocial issues that can be caused by acne, says Jonette E. Keri, M.D., Ph.D.

Oral contraceptive pills and antiandrogen therapies may rival antibiotics for women with acne, according to research presented by Rachel V. Reynolds, M.D. at AAD earlier this month.

Unlike prior generations of dermatologic drugs, Janus kinase (JAK) inhibitors show potential for treating numerous dermatologic indications. Brett King, M.D., Ph.D. explored what this class of drug has to offer in his presentation during AAD earlier this month.

With several Janus kinase (JAK) inhibitors undergoing clinical trials for vitiligo, their potential approvals will deliver new hope and an entirely new treatment strategy, said an expert at AAD.